Vaccine delivery methods using viral vectors
A Bråve, K Ljungberg, B Wahren… - Molecular …, 2007 - ACS Publications
Viral vectors have different capabilities as gene delivery vehicles for vaccines and
immunotherapeutics. This review discusses selected viral vector systems and plasmid DNA and …
immunotherapeutics. This review discusses selected viral vector systems and plasmid DNA and …
Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment
…, J Gerhardt, U Nyman, L Gudmundsdotter, A Bråve… - PloS one, 2009 - journals.plos.org
Background Electrical pulses have been used to enhance uptake of molecules into living
cells for decades. This technique, often referred to as electroporation, has become an …
cells for decades. This technique, often referred to as electroporation, has become an …
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara
…, C Nilsson, B Hejdeman, A Bråve… - The Journal of …, 2008 - academic.oup.com
Background. A human immunodeficiency virus (HIV) vaccine that limits disease and
transmission is urgently needed. This clinical trial evaluated the safety and immunogenicity of an …
transmission is urgently needed. This clinical trial evaluated the safety and immunogenicity of an …
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania
…, K Godoy-Ramirez, A Joachim, VR Polonis, A Bråve… - Vaccine, 2011 - Elsevier
BACKGROUND: We conducted a phase I/II randomized placebo-controlled trial with the aim
of exploring whether priming with a low intradermal dose of a multiclade, multigene HIV-1 …
of exploring whether priming with a low intradermal dose of a multiclade, multigene HIV-1 …
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery
A Bråve, K Ljungberg, A Boberg, E Rollman… - Molecular Therapy, 2005 - cell.com
Gene vaccination encounters problems different from those of gene therapy since both a short
half-life of the gene and a strong immune response to the gene product are desirable. We …
half-life of the gene and a strong immune response to the gene product are desirable. We …
[HTML][HTML] High prevalence of SARS-CoV-2 Omicron infection despite high seroprevalence, Sweden, 2022
…, KV Asin, S Zanetti, ML Karlberg, A Bråve… - Emerging Infectious …, 2023 - ncbi.nlm.nih.gov
We performed 2 surveys during 2022 to estimate point prevalences of SARS-CoV-2 infection
compared with overall seroprevalence in Sweden. Point prevalence was 1.4% in March …
compared with overall seroprevalence in Sweden. Point prevalence was 1.4% in March …
Rapid emergence of omicron sublineages expressing spike protein R346T
…, KV Asin, S Zanetti, ML Karlberg, A Bråve… - The Lancet Regional …, 2023 - thelancet.com
Although vaccinations and SARS-CoV-2 infections have resulted in a high level of antibody-positive
individuals SARS-CoV-2 omicron variants continue to spread, including with high …
individuals SARS-CoV-2 omicron variants continue to spread, including with high …
Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference
AL Ross, A Bråve, G Scarlatti, A Manrique… - The Lancet infectious …, 2010 - thelancet.com
The search for an HIV/AIDS vaccine is steadily moving ahead, generating and validating new
concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and …
concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and …
Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA
AK Zuber, A Bråve, G Engström, B Zuber, K Ljungberg… - Vaccine, 2004 - Elsevier
We evaluated the compound imiquimod as a possible adjuvant for DNA immunization against
human immunodeficiency virus (HIV). We found that gene-gun epidermal delivery of the …
human immunodeficiency virus (HIV). We found that gene-gun epidermal delivery of the …
HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA/MVA vaccinees: a phase I randomized trial
…, K Godoy-Ramirez, T Tecleab, G Scarlatti, A Bråve… - PloS one, 2015 - journals.plos.org
Background We compared safety and immunogenicity of intradermal (ID) vaccination with
and without electroporation (EP) in a phase I randomized placebo-controlled trial of an HIV-…
and without electroporation (EP) in a phase I randomized placebo-controlled trial of an HIV-…
